Halia Therapeutics

Halia Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medications to combat inflammation. Their lead asset, HT-6184, is a first-in-class NLRP3/NEK7 inflammasome inhibitor currently in Phase II clinical trials for various inflammatory diseases. The company also has programs developing LRRK2 inhibitors for neurological diseases.

Buy Funded Startups lists

Funding Round: Series C

Funding Amount: $30M

Date: 31-Jan-2024

Investors: Todd Pedersen

Markets: Biopharmaceuticals, Inflammation, Neurology, Biotechnology, Medical, Pharmaceutical

HQ: Lehi, Utah, United States

Founded: 2017

Website: https://www.haliatx.com

LinkedIn: https://www.linkedin.com/company/halia-therapeutics-inc/

Twitter: https://twitter.com/Halia_Tx

Instagram: